Treating Patients with SCLC with Driver Mutations

Supporting data for the designation comes from the ARTEMIS-001 trial evaluating preliminary safety and antitumor activity of GSK’227 in solid tumors.

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

The overall survival data in the phase 3 KeyVibe-008 trial met the prespecified futility criteria.

In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.

Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.

Treatment with durvalumab raises no new safety signals among patients with limited-stage small cell lung cancer in the phase 3 ADRIATIC trial.